Drug updated on 9/4/2024
Dosage Form | Capsule (oral; 150 mg) |
Drug Class | Isocitrate dehydrogenase-1 inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
Latest News
Summary
- Rezlidhia (olutasidenib) is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
- This summary is based on the review of one randomized controlled trial(s). [1]
- In patients with relapsed or refractory acute myeloid leukemia (AML), monotherapy with the drug achieved an overall response rate of 41% (95% CI 21-64), while combination therapy with Azacitidine showed a slightly higher response rate of 46% (95% CI 27-67).
- For treatment-naive AML patients, the overall response rate was 25% (95% CI 1-81) with monotherapy, significantly increasing to 77% (95% CI 46-95) when used in combination with Azacitidine.
- Common Grade 3-4 Treatment-Emergent Adverse Events (TEAEs): Monotherapy in AML patients resulted in thrombocytopenia (28%, 9/32), febrile neutropenia (22%, 7/32), and anemia (22%, 7/32). Combination therapy led to higher incidences of thrombocytopenia (41%, 19/46), febrile neutropenia (28%, 13/46), neutropenia (28%, 13/46), and anemia (20%, 9/46).
- Mortality: The mortality rate was 34% (11/32) in the monotherapy group and 20% (9/46) in the combination therapy group. The most common cause of death in both groups was disease progression (9%). No deaths were considered study-drug related.
- The study focused on patients aged 18 years or older with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) harboring mutant IDH1, with an Eastern Cooperative Oncology Group performance status of 0-2. Key findings for these groups include a higher overall response rate in treatment-naive AML patients with combination therapy (77%) compared to monotherapy (25%), and a safety profile indicating a higher incidence of grade 3-4 treatment-emergent adverse events, particularly in the combination therapy group. Mortality was higher in the monotherapy group (34%) compared to the combination therapy group (20%).
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Rezlidhia (olutasidenib) prescribing information. | 2022 | Rigel Pharmaceuticals, Inc. South San Francisco, CA |
Randomized Controlled Trials
Document Title | Sex Distribution | Year | Source |
---|---|---|---|
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. | 78Subjects F: 51% M: 49% | 2022 | The Lancet |
Sex Distribution:
F:51%
M:49%
78Subjects
Year:
2022
Source:The Lancet